|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400080991 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-20 09:56:27 |
|
注册时间: Date of Registration: |
2024-02-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
针刺治疗女性性功能障碍的临床随机对照研究 |
|
Public title: |
A Randomized Controlled Clinical Study on Acupuncture for Female Sexual Dysfunction |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针刺治疗女性性功能障碍的临床随机对照研究 |
|
Scientific title: |
A Randomized Controlled Clinical Study on Acupuncture for Female Sexual Dysfunction |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
雷旭露 |
研究负责人: |
雷旭露 |
|
Applicant: |
Lei Xulu |
Study leader: |
Lei Xulu |
|
申请注册联系人电话: Applicant telephone: |
+86 132 6020 5482 |
研究负责人电话: Study leader's telephone: |
+86 132 6020 5482 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lxl2524@126.com |
研究负责人电子邮件: Study leader's E-mail: |
lxl2524@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区北宫镇东山坡三里甲60号 |
研究负责人通讯地址: |
北京市丰台区北宫镇东山坡三里甲60号 |
|
Applicant address: |
60 Sanlijia, Dongshanpo, Beigong Town, Fengtai District, Beijing |
Study leader's address: |
60 Sanlijia, Dongshanpo, Beigong Town, Fengtai District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100072 |
研究负责人邮政编码: Study leader's postcode: |
100072 |
|
申请人所在单位: |
北京市丰台中西医结合医院 |
||
|
Applicant's institution: |
Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine |
||
|
研究负责人所在单位: |
北京市丰台中西医结合医院 |
||
|
Affiliation of the Leader: |
Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024013101 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京市丰台中西医结合医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-05 00:00:00 |
||
|
伦理委员会联系人: |
周晨 |
||
|
Contact Name of the ethic committee: |
Zhou Chen |
||
|
伦理委员会联系地址: |
北京市丰台区北宫镇东山坡三里甲60号 |
||
|
Contact Address of the ethic committee: |
Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 132 6020 5482 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
lxl2524@126.com |
|
研究实施负责(组长)单位: |
北京市丰台中西医结合医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区北宫镇东山坡三里甲60号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
60 Sanlijia, Dongshanpo, Beigong Town, Fengtai District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
院所协同创新科研专项基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Institute collaborative innovation research Special fund |
||||||||||||||||||||||
|
Target disease: |
Female Sexual Dysfunction |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本项目立足妇科常见疾病,选用针刺疗法,从临床疗效、安全性、依从性角度初步评价针刺治疗女性性功能障碍的临床疗效,为以后临床治疗女性性功能障碍提供新方案,为今后开展多中心、大样本临床研究奠定基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on common gynecological diseases, this project selects acupuncture therapy to preliminatively evaluate the clinical efficacy of acupuncture in the treatment of female sexual dysfunction from the perspective of clinical efficacy, safety and compliance, providing a new program for future clinical treatment of female sexual dysfunction, and laying a foundation for future multi-center and large-sample clinical studies. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合FSD的诊断标准。 ②其它治疗无效或不满意者。 ③知情同意,并且签署知情同意书者。 |
||||||||||||||||||||||
|
Inclusion criteria |
① It meets the diagnostic criteria of FSD. ② Other treatment is ineffective or unsatisfactory. ③ Informed consent, and signed the informed consent. |
||||||||||||||||||||||
|
排除标准: |
① 患有女性生殖道畸形者; ② 盆腔器官脱垂≥Ⅱ期患者; ③ 急性生殖道感染(例如生殖道疱疹、假丝酵母菌、滴虫、细菌感染等)者; ④ 既往曾有网片的盆底重建手术者; ⑤ 既往有阴式手术史或经阴道操作史者; ⑥ 急性或复发性尿路感染者; ⑦ 节育环为金属材质或体内有金属植入物者; ⑧ 患有恶性肿瘤、严重心、脑、肾等系统和精神疾病以及其他影响研究依从性的慢性疾病; ⑨ 存在严重的精神心理障碍或疾病,以及存在影响疾病评估效果的精神或心理疾病者; ⑩ 口服药物可对正常性反应周期产生影响者。 ? 因心理因素产生 FSD 症状者等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① Patients with malformations of the female reproductive tract; ② Pelvic organ prolapse ≥ stage Ⅱ patients; ③ Acute reproductive tract infection (such as genital herpes, candida, trichomonas, bacterial infection, etc.); ④ Pelvic floor reconstruction with mesh in the past; ⑤ Previous history of vaginal surgery or vaginal operation; ⑥ Acute or recurrent urinary tract infection; ⑦ The IUD is made of metal or has metal implants in the body; ⑧ Patients with malignant tumors, serious heart, brain, kidney and other systemic and mental diseases, and other chronic diseases that affect study compliance; ⑨ Have serious mental disorders or diseases, and have mental or mental diseases that affect the effectiveness of disease assessment; ⑩ Oral drugs can affect the normal sexual response cycle. ? Developing FSD symptoms due to psychological factors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-08 00:00:00至 To 2025-03-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-02-21 00:00:00 至 To 2025-02-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用随机设计,严格按照诊断标准、纳入标准、排除标准筛选病例,确认入组后,由SPSS22.0计算机软件产生随机区组编号,直至完成总观察例数后结束试验。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Cases were screened strictly according to the diagnostic criteria, inclusion criteria, and exclusion criteria. After the inclusion was confirmed, the SPSS 22.0 computer software generated the random block number until the total number of observed cases was completed. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
贯彻盲法精神,在数据资料统计分析时确保试验者、观察者、资料收集者分离,统计分析工作由专人进行。 |
|
Blinding: |
To carry out the spirit of blinding, ensure that the experimenter, observer and data collector are separated during the statistical analysis of data, and the statistical analysis is carried out by special personnel. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
excel, spss 22.0 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
exce,l spss 22.0 |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |